Gilead and Merck to unveil detailed Phase 3 results of once‑weekly oral HIV regimen at AIDS 2026; Dimension Capital launches $800M fund

Gilead Sciences and Merck announced that they will present detailed results from their Phase 3 trials of a once‑weekly oral HIV treatment regimen at the upcoming AIDS 2026 conference.

The data will cover efficacy and safety outcomes from the late‑stage studies, giving clinicians and investors a clearer view of the regimen’s performance compared with existing therapies.

Separately, venture firm Dimension Capital disclosed the creation of an $800 million fund aimed at backing biotech and life‑science companies, underscoring continued investor interest in the sector.

Both announcements highlight ongoing innovation in HIV therapeutics and sustained capital support for pharmaceutical development.